These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34775888)

  • 1. Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
    Yue X; Hincapie AL; Li Y; Guo JJ
    Leuk Lymphoma; 2022 Apr; 63(4):946-954. PubMed ID: 34775888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
    Li N; Zheng B; Cai HF; Yang J; Luo XF; Weng LZ; Zhan FM; Liu MB
    Clin Drug Investig; 2018 Jan; 38(1):79-86. PubMed ID: 29027641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
    Hirt C; Iannazzo S; Chiroli S; McGarry LJ; le Coutre P; Stenke L; Dahlén T; Lipton JH
    Appl Health Econ Health Policy; 2019 Aug; 17(4):555-567. PubMed ID: 31168745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
    Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
    J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
    Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
    Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
    Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
    J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
    Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
    Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting.
    Muresan B; Mamolo C; Cappelleri JC; Postma MJ; Heeg B
    Appl Health Econ Health Policy; 2021 Nov; 19(6):929-940. PubMed ID: 34250585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
    Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
    Jabbour E; Kantarjian H; Cortes J
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
    García Molina A
    Farm Hosp; 2024; 48(5):T222-T229. PubMed ID: 39013681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
    Garcia Molina A
    Farm Hosp; 2024; 48(5):222-229. PubMed ID: 38679535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
    Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
    Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
    Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.